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Histiocytes, a subtype of white blood cells, originate from CD34+ precursor stem 
cells in the bone marrow through the control of granulocyte-macrophage stimulating 
factor (GM-CSF), macrophage stimulating factor (M-CSF), interleukin (IL)-4 and tumor 
necrosis factor-α (TNF-α) [10, 24, 39]. Histiocytes are commonly found in the ubiquitous 
tissues, including the lymph nodes, spleen, liver (as Kupffer cell) and lung (as alveolar 
macrophages). These immune cells play important roles in the antigen presentation and 
phagocytosis in the reticuloendothelial system (also known as the mononuclear 
phagocytic system), which is closely associated with both the innate and adaptive immune 
responses of the eukaryote. Generally, histiocytes can be divided into 2 main cell types; 
myeloid dendritic cells (DC) and macrophages based on cytokines released, cell-surface 
markers and their primary functions [22].  
DCs belong to antigen presenting cells (APCs) that play a critical role in the 
adaptive immune system. Two main functions of DCs are antigen presentation to CD4+ 
T-cells in the initial stage of immune response and naïve T-cell stimulation. Furthermore, 
the cells also maintain the survival of B-cells resulting in prolonged immune memory. On 
the basis of immunophenotypic and ultrastructural characterization along with cellular 
location, in human, DCs can be classified into follicular DCs (FDC), Langerhans cells, 
interstitial DCs (iDC), veiled cells (also known as indeterminate cell) and interdigitating 
DCs [3, 50]. In dog, these cells are subdivided into epidermal DC (also known as 
Langerhans cell), iDC and interdigitating DC in T-cell domain of lymphoid organs [24, 
39, 42].  
For macrophage differentiation, circulating monocytes migrate into tissues and 
subsequently develop into tissue or resident macrophages, which are important for the 
innate immune system. Macrophages predominantly have phagocytic capability to 
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destroy or against invading pathogens as well as foreign bodies to the host. In addition, 
they also maintain the tissue homeostasis [26]. Currently, macrophages can be classified 
into classical activated M1 macrophages and alternatively activated M2 macrophages 
based on producing cytokines and their functions [19, 71]. Furthermore, M2 macrophages 
are subclassified into M2a, M2b and M2c macrophages based on stimulating cytokines 
[26, 66]. Functionally, M1 macrophages mainly phagocytize and destroy many 
pathogens, and have an important role against tumor growth. These cells secrete various 
types of bioactive factors consisting of reactive oxygen species (ROS), inducible nitric 
oxide synthase (iNOS; also known as nitric oxide synthase 2 (NOS2)) and pro-
inflammatory cytokines such as IL-6, IL-12 and tumor necrotic factor (TNF) that lead 
tumor cells to destruction. Conversely, M2 macrophages normally release a variety of 
growth factors such as epidermal growth factor (EGF), fibroblast growth factor (FGF), 
ascular endothelial growth factor (VEGF), transforming growth factor beta 1 (TGFβ1) 
and matrix metallopeptidase (MMP) leading to wound healing and tissue remodeling in 
normal tissues. These factors, moreover, promote tumor cell survival, tumor proliferation, 
tumor invasion and metastasis [60, 71].  
Histiocytic disorders or histiocytic proliferative disorders (HPDs) are included in 
a group of histiocytic diseases characterized by a variety of clinical presentations and 
pathological characterizations. Other than human, the HPDs are also documented in 
various animal species, for instance, dogs, cats, horse, cattle, pig and exotic pets [6, 8, 27, 
30, 37, 46, 54]. Nowadays, although there are a lot of reports regarding HPDs, their 
etiology as well as pathogenesis are still unclear [1, 3, 27, 62].  In canine literatures, HPDs 
were first described in a Bernese mountain dog in 1970s [3, 24]. Recently, canine HPDs 
are categorized into 1) non-neoplastic histiocytic (reactive histiocytosis (RH)) and 2) 
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neoplastic histiocytic diseases (cutaneous histiocytoma and histiocytic sarcoma) based on 
the clinical behaviors and pathological characterizations [11, 24, 39].  
 RH, a proliferative form of HPDs, is well documented that originates from 
mature/dermal DCs (also known as interstitial DCs). RH was first described in 9 dogs in 
1986 [38, 47]. Generally, RH can be subclassified into cutaneous and systemic RH based 
on the number of organs involved, and on the patterns and distribution of lesions [2]. In 
cutaneous RH, grossly, the lesions are normally confined to the dermis of the head, neck, 
extremities, scrotum and trunk [47]. Conversely, the lesions of systemic RH are usually 
observed in the lymph nodes, eyes, liver, spleen, bone marrow and lung [40, 47, 52]. 
Immunophenotypically, these tumors commonly exhibit CD1a, CD4, CD11c and CD90 
(Thy-1) and the immunohistochemical expression pattern of the tumor cells is consistent 
with the characteristics of dermal DC [2, 13, 39].  
 In normal tissues, epidermal or immature DCs, namely Langerhans cells generally 
reside in the basal and the suprabasal layer of the epidermis, and stratified squamous 
epithelium of  the urogenital system [15]. Like in other types of DCs, Langerhans cells 
play an important role in presenting antigen to T lymphocytes in the adaptive immune 
system. They will migrate to adjacent draining lymph nodes through lymphatic vessels 
and subsequently differentiate into mature DCs within these lymphoid tissues [14, 53, 
65]. “Histiocytoma” and “canine cutaneous histiocytoma (CCH)” are benign forms of 
HPDs that arise from Langerhans cells. Normally, CCH is predominantly found in young 
animals, particularly less than 2 years of age [17]. The typical gross lesion is a solitary 
mass with or without ulceration and alopecia at the epidermis, particularly in the ear pinna 
and extremities. Furthermore, multiple skin masses of CCH are also demonstrated with 
the term of “Langerhans cell histiocytosis” [39, 44]. As mentioned before, gross lesions 
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as well as the cellular morphological features of both RH and CCH are similar. However, 
the distribution patterns of proliferative/neoplastic histiocytes among the layers of the 
skin; top-heavy and bottom-heavy lesions, can be used as a basic histological criterion to 
define CCH and RH, respectively [39, 47]. Although said so, immunohistochemistry 
(IHC) is highly recommended in order to discriminate tumor cell origins. Far from 
immunophenotype of RH, the tumor cells of CCH usually express CD1a, CD1b, CD1c, 
major histocompatibility complex class II (MHCII), CD11c, CD18, intracellular adhesion 
molecule 1 (ICAM-1 or CD54) and E-cadherin [12, 24, 39, 43, 48]. Puff et al [51], 
moreover, mentioned that CCH expressed matrix metalloproteinases (MMPs).  
 Histiocytic sarcoma (HS), a malignant form of HPDs, is a fatal and aggressive 
hematopoietic neoplasm with a worsen prognosis in both human and animals. The lesions 
commonly found in the skin and visceral organs, particularly lymphoid organs. In dogs, 
most of the HS cases originate from DCs. However, cases that arise from the macrophage 
lineage have been illustrated in the term of “hemophagocytic histiocytic sarcoma”. 
Histologically, neoplastic histiocytes are notably pleomorphic and atypical with various 
number of mitotic figures. Distant metastases are very common. Immunohistochemical 
studies demonstrated that these HS cells exhibit CD1, CD11c, CD18, ICAM-1 and 
MHCII [12, 39], which are consistent with the IHC results of DCs. Conversely, 
hemophagocytic HS cells express CD11d instead of CD11c, supporting that these cells 
originate from the macrophage lineage [39, 42].  
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INTRODUCTION 
 In veterinary literatures, histiocytic sarcoma (HS), a histiocytic malignancy, has 
been well documented in dogs and cats [1, 20, 23, 30, 40, 45, 54, 69]. However, other 
animal species including cattle, horses and exotic pets were reported sporadically [5, 6, 
8, 33, 46]. Lymphoid organs (i.e. spleen and lymph nodes), liver, lung and skin are 
recognized as the primary lesion of HS in the animals mentioned above.  
 In the dog, HS occurs most frequently in middle-aged to older purebred dogs, 
predominantly in the Bernese mountain dog, Retriever and Rottweiler [1, 11, 24, 39, 56]. 
Moreover, the Pembroke Welsh corgi, Shetland sheep dog and other purebreds are also 
described sporadically [3, 28, 30, 63, 64, 72]. On the other hand, the occurrence of HS in 
young animals is also illustrated in the Perro de Presa Canario dog [18] and Great Dane 
[36]. The clinical presentations vary depending upon the tumor distribution. Recently, 
several studies have well documented that canine HS mainly originates form myeloid 
dendritic cells (DC), whereas another type, macrophage origin, is very rare [42, 59]. In 
accordance with the latter type, unlike dendritic cell origin, all the lesions are specifically 
confined to the splenic red pulp and bone marrow resulting in splenomegaly or 
hepatosplenomegaly without grossly visible masses. These neoplastic histiocytes show 
marked hemophagocytosis and express major histocompatibility complex class II 
(MHCII), CD18 and CD11d, which are macrophage phenotypes [42, 59]. HSs, moreover, 
is classified into localized and disseminated forms in accordance with the distribution 
pattern, including the numbers of primary organ involvement and the evidence of distant 
metastasis. The localized form is recognized as a solitary mass that mainly manifests in 
the skin and subcutis of the extremities with local invasion of sentinel lymph node. In the 
disseminated form, on the contrary, multiple masses occur preferentially in the spleen, 
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lung and bone marrow with a rapid and widespread metastasis [3]. Despite canine HSs 
are clearly categorized into 2 different forms, the histological and immunohistochemical 
(IHC) features between localized and disseminated HS are identical [24, 30].  
As mentioned before, the primary lesions of HS are commonly found in the 
visceral organs and skin, whereas the occurrence in the central nervous system (CNS) is 
considered to be unusual [62]. The pathological features of HS in the CNS and extraneural 
organs, moreover, have not been described. Therefore, the aim of this chapter is to 
elucidate the histological and IHC features of 54 canine HS cases between neural and 
extraneural organs.  
 
MATERIALS AND METHODS 
Animals 
 Tumor samples from 54 dogs (45 biopsies and 9 necropsies) between 2009 and 
2015 were submitted to Department of Veterinary Pathology, Graduate School of 
Agricultural and Life Sciences, the University of Tokyo for pathological examination. All 
the tumors were histologically diagnosed as HS. The signalment, clinical presentations, 
and tumor location and distribution were summarized in Table 1.1. In accordance with 
tumor location, the 54 dogs were divided into 2 groups; 1) HS with the central nervous 
system involvement (HS-CNS) and 2) HS without the central nervous system 
involvement (HS-NCNS). 
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Histological examination 
The tissue samples were fixed in 10% neutral buffered formalin solution and then 
routinely embedded in paraffin. All tissue sections (2 – 4 µm-thick) were stained with 
hematoxylin and eosin (HE) and then observed under a light microscope. In order to 
determine the mitotic index (MI), 10 areas with a highest density of mitotic figures were 
randomly selected and the total number of mitoses was counted per 10 high power fields 
(hpf; 400X).  
 
Immunohistochemical examination 
 All the sections, after antigen retrieval, were immersed in 10% hydrogen peroxide 
(H2O2) in methanol at room temperature for 5 min and subsequently incubated in 8% 
skim milk at 37oC for 30 min in order to block non-specific reactions. All the tissues were 
reacted with each primary antibody at 4oC overnight. The primary antibodies used and 
antigen retrieval methods are detailed in Table 1.2. The horseradish peroxidase (HRP)-
labeled polymer reagent (Envision+ system-HRP labeled polymer reagent, Dako, Tokyo, 
Japan) was applied at 37oC for 40 min. For the detection of CD208, the sections were 
reacted with a biotinylated secondary antibody (1:400, anti-rat IgG (H+L) antibody, KPL, 
MD) at 37oC for 1 hr, and then incubated with streptavidin/HRP reagent (1:300, Dako, 
Glostrup, Denmark) at room temperature for 40 min. All the sections were rinsed with 
Tris-buffered saline (TBS) prior to treating with a 3-3’-diaminobenzidine solution 
containing 0.03% H2O2, and counterstained with Mayer’s hematoxylin (Muto Pure 
Chemicals, Tokyo, Japan). Normal canine tissues, moreover, were used as positive 
controls, whereas negative controls were performed through applying TBS instead of the 
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primary antibodies. For immunohistochemical scoring, positive tumor cells were counted 
in five randomly selected areas (hpf; 400X). Semiquantitative scores were divided into 4 
categories as follows: - (negative) = no positive tumor cells, + (weakly positive) = 1 – 
25% positive tumor cells, ++ (moderately positive) = 26 – 50% positive tumor cells and 
+++ (strongly positive) = >50% positive tumor cells. In addition, the Ki67 and PCNA 
expression was also determined by counting the number of positive nuclei in 10 randomly 
selected areas (hpf; 400X). The average percentage of positive cells was defined as Ki67- 
and PCNA-proliferative indices. 
 
Statistical analyses 
Chi-square or Fisher’s exact test was used to assess the association between tumor 
distribution and primary tumor origins, as appropriate. Mann-Whitney U test was 
performed to determine the significance of the difference of the mean MI, Ki67 and 
PCNA indices of proliferative activity and the difference of the expression of 
immunohistochemical markers between HS-CNS and HS-NCNS groups. The Ki67 and 
PCNA indices were demonstrated as mean ± standard error (SE). Two-sided significant 
level was used that p<0.05 was considered statistically significant.  
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RESULTS 
Clinicopathological features 
 The 54 dogs examined included 31 males and 23 females (male: female ratio = 
1.35:1) with a range of 3 years to 14 years (median age = 9 years and 4 months). The 
breeds were comprised of Pembroke Welsh corgis (n = 15), Flat coated retrievers (n = 
11), Bernese mountain dogs (n=3), Beagle (n = 3), Mongrels (n = 3), Shetland sheepdogs 
(n = 3), Golden retrievers (n = 2), Labrador retrievers (n = 2), Miniature dachshunds (n = 
2), Miniature schnauzers (n = 2), Basset hound (n = 1), Norfolk terrier (n = 1), Pointer (n 
= 1), Pomeranian (n = 1), Rottweiler (n = 1), Shiba (n = 1), Siberian husky (n = 1) and 
unknown breed (n = 1) (Fig. 1.1). Various clinical signs were recorded depending upon 
the numbers of primary and/or distant organ involvement. On the basis of tumor 
distribution, the tumors were classified into localized (n = 41) and disseminated (n = 13) 
(Table 1.1). As mentioned above, all the samples were divided into HS-CNS (n = 23) and 
HS-NCNS (n = 31), and the latter was detected in the spleen and lymphoid organs (n = 
10), limbs (n = 6), lung (n = 5), oral cavity (n = 3), gastrointestinal tracts (n = 2), thoracic 
wall (n = 2), abdominal cavity (n = 1), and skin and subcutis (n = 1) (Fig. 1.2). We found 
that there has been strong significant association between the tumor distribution and their 
origin (p<0.001).  
 
Histological examination  
 Microscopically, all the tumor samples were poorly demarcated. Most of the cases 
contained numerous round to pleomorphic cells that arranged in a sheet or a solid pattern. 
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These cells had clear eosinophilic cytoplasm with distinct borders. Their nuclei were 
eccentric with a round to polygonal shape. The prominent magenta-colored nucleoli (1 – 
2 nucleoli/nucleus) were observed. Moderate to marked cellular atypia including 
anisocytosis, anisokaryosis and anisonucleoliosis was noted. Bizarre mononuclear and 
multinucleated giant tumor cells interspersing within tumor lesions were commonly 
found (Fig. 1.3). Cytoplasmic vacuolation and hemophagocytosis were occasionally 
observed, particularly in hemophagocytic histiocytic sarcoma (cases No. 30 – 33; Fig. 
1.4). In some cases, the shape of tumor cells was predominantly spindle to fusiform and 
the cells were arranged in an irregular pattern. These cells had a moderate amount of 
eosinophilic cytoplasm with indistinct borders. The nuclei were concentric and usually 
ovoid- to spindle-shaped. The nucleoli were occasionally found. Mild atypia was noted 
(Fig. 1.5). Although, various numbers of atypical mitoses were observed in all the cases, 
the HS-CNS group had higher MIs than those in the HS-NCNS group (p<0.05; Table 1.3 
and Fig. 1.6). Moreover, moderate to large numbers of small lymphocytes often admixing 
with plasma cells were commonly found in the lesions of all 54 cases (Fig. 1.7). Tumor 
necrosis were occasionally observed.  
 
Immunohistochemical examination  
Moderate to strong cytoplasmic or membrane staining for HLA-DR, Iba-1 and 
CD204 was found in all the cases. Cytoplasmic and membrane immunoreactivities to 
CD163 were variably distributed in 42 cases. Twenty-two cases had moderate to strong 
cytoplasmic staining for lysozyme. Variable or weak cytoplasmic and/or nuclear 
immunoreactivity to S100 were noted in 17 cases. In addition, a patchy dot-like 
13 
 
cytoplasmic immunoreactivity to CD208 was observed in 25 cases (Table 1.3 and Fig. 
1.8).  Tumor cells were negative for myeloid/histiocyte antigen (MAC387) in all the 
cases. There was a significant difference in CD204 immunoreaction between HS-CNS 
and HS-NCNS groups (p<0.05), whereas the immunoreactivities of other markers 
showed no significant differences between them (Fig. 1.9). Ki67 and PCNA proliferative 
indices ranged 0.5 – 67.9% (average 31.1±2.4%) and 19.1 – 95.1% (average 62.6±1.9%), 
respectively (Table 1.3 and Fig. 1.9).  
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DISCUSSION 
 In this chapter, histopathological and immunohistochemical features of 54 canine 
HS cases were examined. Based on tumor locations, all the tumors were divided in to HS 
with CNS involvement (HS-CNS; n = 23) and HS without CNS involvement (HS-NCNS; 
n = 31). The occurrence of canine HS was higher in male than in female as demonstrated 
previously [3, 42, 58, 63]. The Pembroke Welsh corgi and Flat coated retriever were most 
frequently affected in HS-CNS and HS-NCNS, respectively. These occurrence tendency 
was consistent with that described previously [11, 30, 35]. Other purebreds such as the 
Shetland sheepdog, Bernese mountain dog and Golden retriever were affected 
sporadically. This observation suggests that a genetic factor possibly contributes the 
occurrence of canine HS. All the HS cases presented various types and degrees of clinical 
signs (Table 1.1). This suggests that symptoms in dogs with HS is relatively non-specific 
and seems to depend upon organs involved. Among the 54 cases, 41 were the localized 
HS and 13 were disseminated. Interestingly, only the localized form was observed in HS-
CNS group, showing that distant metastases from primary CNS tumors may be an unusual 
phenomenon and that localized HS is a common form of HS with CNS involvement. 
Although cellular morphology of HS-CNS and HS-NCNS were not different, MI in the 
former was significantly higher than the latter. This suggests that HS derived from CNS 
may have a more aggressive biological behavior than HS of extraneural origin.  
 The present results revealed that mitotic index in HS derived from CNS was 
higher than that arose from the extraneural organs. This observation suggests that 
biological behaviors of HS with CNS involvement is relatively more aggressive than HS 
occurring in other organs.  
15 
 
 In general, pathological diagnosis of HS is often challenging. The cellular 
morphology of HS cases varied from round to pleomorphic-shaped with marked atypia, 
which mimics histological features of other hematopoietic tumors, malignant melanoma 
and undifferentiated carcinoma. Therefore, immunohistochemistry is highly 
recommended in order to identify the tumor types. The present results showed that all the 
tumor cases (n=54) had an intense IHC staining for major histocompatibility complex 
class II (MHCII), Iba-1 and CD204. These molecules are comprehensive markers for the 
diagnosis of histiocytic diseases in both human and animals. These results strongly 
suggest that all the present cases had a histiocytic differentiation.  
Tumor cells of the majority of the present HS cases were positive also for CD163 
(hemoglobin scavenger receptor) that is specific for the monocyte/macrophage lineage 
[7, 31]. This marker is usually used for detecting tumor associated macrophages (TAMs) 
within tumor lesions [19, 71]. Therefore, the present neoplastic histiocytes derived from 
both neural and extraneural organs might be part of macrophage phenotype. Lysozyme 
(also known as muramidase) is also widely used as one of markers for histiocytes [41]. 
Herein, although all the cases were confirmed as HS, tumor cells in only 22 cases 
exhibited lysozyme, supporting that these cases appeared histiocytic phenotype. 
Conversely, negative immunostaining for lysozyme was observed in 32 cases despite 
positive immunoreactivity to HLA-DR, Iba-1 and CD204. These observations suggest 
that HS cells can dedifferentiate to the stem-like stage or differentiate to another cell 
lineage, which may lead to the lack of lysozyme/muramidase expression [41].  
Recently, S100 protein is widely used for the diagnosis of human histiocytic 
diseases [4, 21, 25, 29, 50, 68, 70] as well as for the detection of human dendritic cells 
[32, 49]. On the other hand, CD208 (also known as dendritic cell-lysosomal associated 
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membrane protein; DC-LAMP), a new DC marker in human, is closely associated with 
DC differentiation and maturation [16]. However, pneumocytes of human, mouse, sheep 
and cattle also exhibit this molecule [55, 57]. Among the 54 present HS cases, 17 were 
positive for S100 and 25 for CD208, suggesting the DC origin of these tumor cells. 
MAC387 is commonly used as a monocyte/macrophage marker in both medical and 
veterinary researches [9, 34, 61, 67]. In the current study, all the tumor cells were negative 
for this molecule. In addition, canine cutaneous histiocytoma and reactive histiocytosis 
did not react for MAC387 (data not shown).  
 There were no significant differences in the expression of the markers between 
HS-CNS and HS-NCNS, reflecting that the immunophenotype of HS cells arising from 
both neural and extraneural organs are identical. However, neoplastic histiocytes from 
CNS tend to exhibit monocyte/macrophage markers than those from extraneural organs. 
Conversely, HS with DC differentiation was frequently found in extraneural organs, 
which is consistent with those described previously [11, 24]. 
 In this chapter, although histological and IHC features between the 2 HS 
categories, HS-CNS and HS-NCNS are identical, the former is relatively more aggressive 
than the latter based on data of mitotic index.  
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Table 1.1 Fifty four cases of canine histiocytic sarcoma 
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Table 1.2 Primary antibodies used for immunohistochemical examination 
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Table 1.3 Mitotic index and immunohistochemical characteristics of 54 dogs with 
histiocytic sarcomas 
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Figure 1.1. Breeds of dogs affected with HS. 
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Figure 1.2. The location of 54 HS cases. The cases were divided into HS-CNS and HS-NCNS groups (a) in accordance with tumor location. 
In HS-NCNS group, the lesions were located in the spleen and other lymphoid organs, limb, lung, oral cavity, gastrointestinal tract, thoracic 
wall, abdominal cavity, and skin and subcutis (b).  
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Figure 1.3. Histiocytic sarcoma. Right hindlimb. Dog. Case No. 37. The tumor contains 
numerous neoplastic histiocytes with severe cellular atypia. These cells have abundant 
eosinophilic cytoplasm. Their nuclei are eccentric and round to polygonal. Prominent 
nucleoli are noted in some tumor cells. Multinucleated giant cells are commonly found. 
The phagocytosis by tumor cells is also observed (arrow). HE. Scale bar = 20 µm. 
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Figure 1.4. Hemophagocytic histiocytic sarcoma. Spleen. Dog. Case No. 30. Numerous 
neoplastic histiocytes expand to the splenic red pulp. These cells contain red blood cells 
hemophagocytosis, (arrowheads) and brown pigments. The latter are positive for Berlin 
blue stain (inset), indicating hemosiderin. The cytoplasmic vacuolation, moreover, is 
occasionally found. HE. Berlin blue (inset). Scale bar = 20 µm (including inset). 
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Figure 1.5. Histiocytic sarcoma. Lung. Dog. Case No. 44. The tumor consists of 
numerous spindle-shaped tumor cells that arrange in a storiform pattern. These cells have 
the eosinophilic cytoplasm with the indistinct border. Their nuclei are oval-shaped with 
prominent nucleoli. Mild cellular atypia is noted. Moderate infiltration of small 
lymphocytes is observed. HE. Scale bar = 20 µm. 
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Figure 1.6. Mitotic index of 54 cases with histiocytic sarcoma. MI of HS-CNS group is 
significantly higher than that of HS-NCNS group. Mann-Whitney U test. *: p<0.05. 
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Figure 1.7. Histiocytic sarcoma. Brain. Dog. Case No. 9. Numerous neoplastic 
histiocytes invade to the brain cortex. The tumor cells are highly pleomorphic and show 
marked phagocytosis (arrowhead). Perivascular lymphocytic cuffing is notably observed 
(asterisk). HE. Scale bar = 20 µm. 
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Figure 1.8. Histiocytic sarcoma. Limb. Dog. Case No. 38. Neoplastic histiocytes are 
strongly positive for HLA-DR (a), Iba-1 (b), CD204 (c), CD163 (d) and CD208 (g), but 
negative for lysozyme (e), S100 (f) and myeloid/histiocyte antigen (MAC387) (h). 
Normal macrophages are also positive for lysozyme (e). IHC. Hematoxylin counterstain. 
Scale bar = 20 µm.  
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Figure 1.9. The % expression of the markers. The percent of CD204-immunopositive 
cells in the HS-NCNS group is significantly higher than that in the HS-NCNS group. No 
significant differences are observed in other markers between the groups. Mann-Whitney 
U test. *: p<0.05. 
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